• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
Adial Pharmaceuticals

Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports no Challenges to European Patent

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the strengthening of its intellectual property (IP) portfolio, as it has successfully passed the patent opposition period in Europe..

Read more →
CivaTech Oncology, Inc. Offers New Technology to Fight Lung Cancer

CivaTech Oncology, Inc. Offers New Technology to Fight Lung Cancer

Physicians are now able to successfully implant a new bio-absorbable, internal radiation treatment known as CivaSheet® to treat a patient with recurrent lung cancer. Approximately 234,000 patients per year in the U.S. are diagnosed with lung cancer, and of those, approximately 30% to 55% of patients with non-small cell lung cancer develop recurrence.

Read more →
QUANTM Irradiation System™ Earns CE Mark Approval

QUANTM Irradiation System™ Earns CE Mark Approval

ARTMS Products today announced it received CE marking approval for its first-in-class, advanced technology QUANTM Irradiation System™ for producing high-value radioisotopes, such as Tc-99m and Ga-68, on medical cyclotrons.

Read more →
Tilray Inc.

Tilray® 2:100 Product Shows Promise in Canada’s First Pediatric Study of Mixed THC/CBD Medical Cannabis Oil for Children with Drug-Resistant Epilepsy

Tilray Inc., a global pioneer in medical cannabis production and distribution, is pleased to announce that a study featuring Tilray 2:100, a medical cannabis oil containing high amounts of cannabidiol (CBD) and conservative amounts of tetrahydrocannabinol (THC), has shown promising results for children with drug-resistant epilepsy (DRE) due to Dravet Syndrome.

Read more →

We use cookies to ensure you get the best experience on this website Privacy Policy